Hundreds of thousands of Europeans die each year from diseases that medicine can prevent. In 2022, approximately 14% of all deaths in the EU, and 725,625 deaths before age 75, stemmed from preventable causes according to Eurostat. The gaps involve financing, in addition to policy implementation. The gaps also concern the capacity of states to transform a policy decision into sustainable infrastructure beyond electoral cycles.
The essentials
- In 2022, approximately 14% of deaths in the EU stemmed from preventable causes according to Eurostat; the 2025 WHO Europe report estimates 1.8 million deaths related to avoidable non-communicable diseases annually in the European Region.
- Implementation remains uneven across states: tobacco control, salt reduction, nutritional labeling advance at varying rates from country to country.
- The execution deficit often stems from institutional obstacles that make it difficult to maintain program continuity beyond electoral cycles.
- The Lyon trial NCT07391462 (2026) tests a digital monitoring architecture that could extend the lifespan of prevention programs beyond mandates.
- The 2030-2035 horizon will likely be one of a fork in the road: either European states build prevention agencies structurally protected from the electoral cycle, or hospital costs and productivity losses decide for them.
A third of deaths is not inevitable
Cardiovascular diseases, tobacco-related cancers, complications from type 2 diabetes: these pathologies kill massively and predictably. They share risk factors that epidemiologists have understood by heart since the 1970s: tobacco, salt, saturated fats, sedentary lifestyles, alcohol. And for each of these factors, there are interventions whose effect on mortality is supported by a body of scientific evidence.
The WHO NCD Progress Monitor 2025 evaluates states’ capacity to implement these interventions. The WHO Europe estimates that approximately 1.8 million annual deaths are avoidable in the European Region, of which 60% are preventable through risk reduction and public health interventions, deployable without cutting-edge technology, often inexpensive to implement. The State of Health in the EU 2025 report, led by the OECD, confirms this diagnosis by adding a budgetary dimension: prevention spending represents less than 3% of total health spending in most member states, while curative and rehabilitation care make up the largest share of spending, at nearly 60% in 2022.
This imbalance is not new. It has been documented, discussed, and lamented for twenty years in European forums. What stands out from 2025 data is that the gap between what states know how to do and what they actually do persists.
Tobacco, salt, and labeling: three lessons in implementation
Let’s take three concrete examples to measure the scale of the problem.
Tobacco control is the best-documented public health intervention in history. High taxes reduce consumption, smoke-free spaces protect non-smokers, advertising bans reduce youth entry into smoking. Each component is validated by decades of data. Yet, according to the 2025 NCD Progress Monitor, several EU member states still have not reached the WHO-recommended threshold for taxes on tobacco products, and enforcement of advertising bans remains uneven.
Salt reduction in processed foods follows the same logic. A drop in average salt consumption of one or two grams per day significantly reduces blood pressure at the population level, and therefore strokes and heart attacks. This intervention involves agreements or regulations on food industry players, without requiring changes in individual behavior. Finland and the United Kingdom, before its departure from the EU, succeeded in sustainably lowering salt levels in processed products, according to 2025 data. The majority of member states have no structured program.
Nutritional labeling on the front of packaging illustrates a third form of resistance. The Nutri-Score, whose effectiveness in guiding consumer choices is supported by studies published in The Lancet and the British Medical Journal, remains optional in Europe. The European Commission announced a regulatory proposal, postponed several times under pressure from food industry lobbies. The result: a mosaic of incompatible national systems, nutritional information illegible for those who travel or shop online, and industrialists applying the rules of the least demanding market.
These three cases tell the same story: scientific evidence is not lacking, examples of success exist, mechanisms are understood. What’s blocking is elsewhere.
The gap between decision and implementation: an institutional problem
Many member states remain behind in implementing prevention policies they have adopted, although some countries have reached premature mortality reduction targets.
The answer lies in a dynamic well described in political science literature. The effects of prevention policies vary widely: some interventions have measurable impact in less than five years, others require a longer horizon. Governments investing in prevention bear immediate political costs: friction with industry, imposed habit changes, fiscal pressure on popular products. Benefits may be reaped by successive governments. Some prevention policies have long-term benefits, but WHO interventions can also produce measurable effects within an electoral cycle.
A second reason relates to administrative organization. Prevention programs require coordination among many ministries: health, agriculture, education, finance, local authorities. This coordination is costly in political energy and administrative time. It does not maintain itself spontaneously and requires institutional architecture explicitly designed to last beyond electoral changes. Many European states have not built this architecture.
National prevention plans often exist on paper and lose force with each ministerial change.
This gap between decision and execution is moreover a subject that extends beyond health. It also affects industrial policy, energy transition, or vocational training, as shown by other analyses in the journal on mental health as the budget line cut first.
The problem specific to chronic disease prevention is that it combines both obstacles: long timeframe and complex coordination. This is what health economists call the “implementation deficit,” distinct from the knowledge deficit. We know what to do. We have not built the conditions to do it sustainably.
Countries that succeeded and why
It would be inaccurate to say that large-scale prevention is impossible. Some states have proven otherwise, and their trajectories deserve to be taken seriously.
Finland is the best-documented case. Starting in the 1970s, the country had cardiovascular disease rates among the highest in Western Europe. The North Karelia Project was launched in 1972 following a local petition and preparation by Finnish health institutions: salt reduction, replacement of saturated fats, awareness campaigns on tobacco. The food industry subsequently participated in certain interventions. Over three decades, cardiovascular mortality fell by more than 80% in the pilot region.
Medical technology was not the central element of this success.
Duration played an important role: the program persisted by embedding itself in local institutions and industrial practices, rather than in a single ministerial plan.
Denmark followed a similar path on salt, working directly with bakers and butchers to reformulate recipes. The result was a measurable drop in average consumption and, according to follow-up studies published in public health journals, an associated reduction in hypertension.
These successes share three characteristics. First, an anchoring in infranational or sectoral institutions that survive government changes. Second, a transformation of food production chains, which makes behavior change unnecessary for the consumer. Finally, rigorous epidemiological monitoring that generates public data, making program abandonment politically costly.
These three characteristics are rarely combined in national plans of the least-progressing member states. The model exists. It is not being transferred.
Building what lasts after the next government
The 2025 WHO report also raises a question of applied political science: whether prevention institutions can be designed to survive electoral cycles.
An hypothesis is emerging in public policy literature: real-time measurement creates a form of institutional accountability that slows disinvestment. A program whose effectiveness is visible quarterly is politically more difficult to abandon than a program whose results will not appear for fifteen years.
This hypothesis is plausible. It rests on a well-documented observation in public policy: programs whose effects are measurable in the short term better resist electoral changes. The issue is therefore less about finding new medical interventions than about building information systems capable of making visible, quickly, what prevention accomplishes.
Other institutional approaches merit examination. Several health economists, some close to the OECD, advocate for prevention agencies with multi-year budgetary autonomy, modeled on central banks or financial regulatory authorities. The idea is to subtract part of prevention decisions from the direct political cycle, by entrusting experts mandated for five to ten years with program responsibility, with defined objectives and an accountability obligation. This model shifts democratic control toward objectives and results, rather than toward annual operational decisions.
This approach encounters legitimate objections. Defining public health priorities involves value choices that belong to political debate. The question of whether combating tobacco takes precedence over reducing sedentariness, or whether a sugar tax is better than school cafeteria reform, involves arbitrations that cannot be entirely delegated to independent agencies without emptying collective choice of its substance.
The tension is real, and it has no simple resolution.
What is certain, however, is that the status quo produces measurable results in lives lost. The 2030-2035 horizon risks being one of a fork in the road. Stable institutional architecture could help moderate the disease burden and hospital costs related to chronic diseases. The others will continue to pay in curative care what they did not invest in prevention, an accelerated aging that will make this calculation increasingly unsustainable.
Demographic aging adds additional pressure. Chronic diseases that prevention could avoid strike harder aging populations, who will be more numerous in 2035 than in 2025. The window to act upstream is narrowing. The costs of inaction are rising. And scientific evidence, it does not change.
Measures already taken by member states and their limits
It would be inaccurate to present Europe as entirely immobile. Several member states have advanced on specific points since 2020.
France has extended the tobacco advertising ban to digital spaces and strengthened nicotine substitute reimbursement. Hungary, despite its contested political record on other fronts, has maintained one of Europe’s highest taxes on processed foods. Belgium has made the Nutri-Score mandatory on national products. These advances exist and must be named.
But the 2025 WHO report shows these measures remain isolated. They often fit in a fragmented way into national strategies, not always linking objectives, multi-year financing, and independent monitoring mechanisms. They respond to occasional political windows: a convinced minister, citizen pressure, a report that momentarily makes noise. When the window closes, momentum fades.
Coherence is also lacking at the European level. The Commission has authority to regulate labeling and food additives, but its nutrition proposals navigate legislative processes where agricultural member states and food industry lobbies exercise constant pressure. The result is European regulation that advances by exception and derogation rather than by progressive standard.
To understand how costly this coordination deficit is, one need only compare it to what Europe invests in digital transformation or energy transition: multi-year programs, guaranteed financing, binding legislative objectives. Compared to other areas of public investment, chronic disease prevention has a less structured institutional framework.
Who can move the lines
Successful experiences suggest that change does not always come from central governments. Cities have played a determining role in several public health transitions. Between 2012 and 2017, Amsterdam reported a relative 12% decline in combined prevalence of overweight and obesity in children, from 21% to 18.5% between 2012 and 2015/16, through an integrated approach involving schools, physical activity, and nutrition, though the report does not allow causally attributing the observed decline to these components alone. This result, published in the British Medical Journal in 2021, was achieved without medical innovation and with a modest budget.
Employers constitute another underexploited lever. Companies investing in preventive health for their employees see absenteeism decline and productivity increase. This alignment of interests between public health and economic performance is well documented, notably in OECD analyses on workplace health. Health systems that successfully engaged employers, such as those in Nordic countries, show cardiovascular prevention rates significantly above the European average.
Civil society also weighed in on lasting transformations. Anti-tobacco associations played a decisive role in adopting smoke-free spaces in several countries, by maintaining constant pressure that outlasted multiple political cycles. This long-term, low-profile work is often the real condition for a policy’s lasting inscription in institutional practices.
The combination of these actors, cities, employers, and associations, with national agencies providing them with data and stable regulatory frameworks, has contributed to results in certain contexts where it has been implemented. It remains unknown whether this architecture can be deliberately reproduced or whether it only emerges from local political configurations difficult to export. Several studies and trials seek to answer this question rigorously. Their results could offer European policymakers better understanding of institutional models capable of sustaining prevention, beyond confirming that it is effective.
Sources
- WHO NCD Progress Monitor 2025 – World Health Organization: https://www.who.int/publications/i/item/9789240090842
- State of Health in the EU Synthesis Report 2025 – OECD/European Commission: https://www.ssph-journal.org/journals/public-health-reviews/articles/10.3389/phrs.2026.1609639/full
- NCT07391462 – Lyon Clinical Trial 2026, ClinicalTrials.gov: https://clinicaltrials.gov
- North Karelia Project – epidemiological documentation, Terveyden ja hyvinvoinnin laitos (Finnish National Institute for Health and Welfare)
- Amsterdam Healthy Weight Approach – results published in the British Medical Journal, 2021
